NasdaqGS:AMRXPharmaceuticals
Does Amneal Pharmaceuticals' (AMRX) Inhaler Push Reveal a Durable Edge in Complex Generics?
Earlier in April 2026, Amneal Pharmaceuticals launched its first U.S. metered-dose inhalers, generic versions of PROAIR HFA and the original QVAR inhalation aerosol, alongside a new generic bimatoprost ophthalmic solution 0.01%, expanding its presence in respiratory and ophthalmic treatments.
These complex generic launches into inhalation and glaucoma care highlight Amneal’s growing capabilities in difficult-to-make products that can broaden patient access and diversify its portfolio.
Next,...